Timeline

Timothée Bruel

Group Leader

26 Sep 2024

publication

Levels and functionality of Pacific Islanders’ hybrid humoral immune response to BNT162b2 vaccination and delta/omicron infection: A cohort study in New Caledonia.

19 Jul 2024

publication

Broad sarbecovirus neutralization by combined memory B cell antibodies to ancestral SARS-CoV-2.

13 Dec 2023

publication

High fusion and cytopathy of SARS-CoV-2 variant B.1.640.1.

14 Jun 2023

publication

Complement-dependent mpox-virus-neutralizing antibodies in infected and vaccinated individuals.

01 Jun 2023

publication

Estimated protection against COVID-19 based on predicted neutralisation titres from multiple antibody measurements in a longitudinal cohort, France, April 2020 to November 2021.

14 Feb 2023

publication

Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies.

24 Jan 2023

team

Antiviral Activities of Antibodies

17 Nov 2022

publication

Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies.

05 Oct 2022

publication

Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection.

01 Sep 2022

publication

Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study.

27 Aug 2022

publication

IRF8 regulates efficacy of therapeutic anti-CD20 monoclonal antibodies.

08 Jul 2022

publication

Kinetics of the SARS-CoV-2 Antibody Avidity Response Following Infection and Vaccination.

04 Jul 2022

publication

Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2.

17 Jun 2022

news

New publication – Potent Human Broadly SARS-CoV-2 Neutralizing IgA and IgG Antibodies Effective Against Omicron BA.1 and BA.2

01 Jun 2022

publication

Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies.

04 May 2022

publication

Identification of DAXX as a restriction factor of SARS-CoV-2 through a CRISPR/Cas9 screen.

12 Mar 2022

publication

Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2.

02 Feb 2022

publication

Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells.

01 Feb 2022

publication

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.

01 Jan 2022

publication

Robust and Functional Immune Memory Up to 9 Months After SARS-CoV-2 Infection: A Southeast Asian Longitudinal Cohort.

01 Nov 2021

publication

Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-alpha or alpha SARS-CoV-2 variants: an observational retrospective study.

17 Sep 2021

publication

Sex Differences in the Evolution of Neutralizing Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2.

01 Sep 2021

publication

Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection.

18 Aug 2021

news

Immune checkpoint inhibitors improve cellular immunity against SARS-CoV-2 infection

01 Aug 2021

publication

Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection.

22 Jul 2021

news

SARS-CoV-2 : induces the dedifferentiation of multiciliated cells and impairs mucociliary clearance

08 Jul 2021

publication

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.

08 Jun 2021

news

Covid-19, un an après : persistance des anticorps protecteurs et réduction significative du risque de réinfection

18 May 2021

publication

Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies.

01 Apr 2021

publication

SARS-CoV-2 infection in schools in a northern French city: a retrospective serological cohort study in an area of high transmission, France, January to April 2020

01 Jan 2021

publication

Characteristics Associated with Olfactory and Taste Disorders in COVID-19.

01 Dec 2020

publication

Syncytia formation by SARS-CoV-2-infected cells.

02 Sep 2020

publication

A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations

01 Sep 2020

publication

Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France.

05 Feb 2020

publication

Anti-HIV-1 antibodies trigger non-lytic complement deposition on infected cells.

15 Oct 2019

project

3D Pasteur

01 Jun 2019

publication

Accelerated thymopoiesis and improved T-cell responses in HLA-A2/-DR2 transgenic BRGS-based human immune system mice.

01 Aug 2018

publication

A human immune system mouse model with robust lymph node development.

23 Feb 2018

publication

Correction: Stage-specific IFN-induced and IFN gene expression reveal convergence of type I and type II IFN and highlight their role in both acute and chronic stage of pathogenic SIV infection.

13 Oct 2017

publication

HIV Fusion in Dendritic Cells Occurs Mainly at the Surface and Is Limited by Low CD4 Levels

14 Jun 2017

publication

Zika virus induces massive cytoplasmic vacuolization and paraptosis-like death in infected cells.

01 May 2017

publication

Broadly neutralizing antibodies suppress post-transcytosis HIV-1 infectivity

15 Mar 2017

publication

Ultrasensitive HIV-1 p24 Assay Detects Single Infected Cells and Differences in Reservoir Induction by Latency Reversal Agents.

15 Mar 2017

publication

CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses

25 Jan 2017

publication

Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies

10 Oct 2016

publication

CD4-mimetic sulfopeptide conjugates display sub-nanomolar anti-HIV-1 activity and protect macaques against a SHIV162P3 vaginal challenge

12 Sep 2016

publication

[Antibodies that kill HIV-1-infected cells]

03 Mar 2016

news

Antibodies capable of eliminating HIV-infected cells

03 Mar 2016

publication

Elimination of HIV-1-infected cells by broadly neutralizing antibodies

01 Jan 2016

publication

Dendritic Cells from HIV Controllers Have Low Susceptibility to HIV-1 Infection In Vitro but High Capacity to Capture HIV-1 Particles.

01 Jul 2015

publication

SAMHD1 Limits HIV-1 Antigen Presentation by Monocyte-Derived Dendritic Cells

11 May 2015

team

Virus and Immunity

14 Jan 2015

publication

Long-term control of simian immunodeficiency virus (SIV) in cynomolgus macaques not associated with efficient SIV-specific CD8+ T-cell responses

26 Nov 2014

publication

IFITM proteins incorporated into HIV-1 virions impair viral fusion and spread

30 Jan 2014

publication

Plasmacytoid dendritic cell dynamics tune interferon-alfa production in SIV-infected cynomolgus macaques

12 Jan 2012

publication

Porcine colon explants in the study of innate immune response to Entamoeba histolytica

21 Dec 2011

publication

Towards the establishment of a porcine model to study human amebiasis

13 Apr 2010

publication

Expression and immunogenicity of the mycobacterial Ag85B/ESAT-6 antigens produced in transgenic plants by elastin-like peptide fusion strategy

06 Jan 2010

publication

A little guide for advanced search:

Levels and functionality of Pacific Islanders’ hybrid humoral immune response to BNT162b2 vaccination and delta/omicron infection: A cohort study in New Caledonia.

Broad sarbecovirus neutralization by combined memory B cell antibodies to ancestral SARS-CoV-2.

High fusion and cytopathy of SARS-CoV-2 variant B.1.640.1.

Complement-dependent mpox-virus-neutralizing antibodies in infected and vaccinated individuals.

Estimated protection against COVID-19 based on predicted neutralisation titres from multiple antibody measurements in a longitudinal cohort, France, April 2020 to November 2021.

Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies.

Antiviral Activities of Antibodies

Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies.

Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection.

Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study.

IRF8 regulates efficacy of therapeutic anti-CD20 monoclonal antibodies.

Kinetics of the SARS-CoV-2 Antibody Avidity Response Following Infection and Vaccination.

Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2.

New publication – Potent Human Broadly SARS-CoV-2 Neutralizing IgA and IgG Antibodies Effective Against Omicron BA.1 and BA.2

Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies.

Identification of DAXX as a restriction factor of SARS-CoV-2 through a CRISPR/Cas9 screen.

Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2.

Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells.

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.

Robust and Functional Immune Memory Up to 9 Months After SARS-CoV-2 Infection: A Southeast Asian Longitudinal Cohort.

Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-alpha or alpha SARS-CoV-2 variants: an observational retrospective study.

Sex Differences in the Evolution of Neutralizing Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2.

Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection.

Immune checkpoint inhibitors improve cellular immunity against SARS-CoV-2 infection

Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection.

SARS-CoV-2 : induces the dedifferentiation of multiciliated cells and impairs mucociliary clearance

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.

Covid-19, un an après : persistance des anticorps protecteurs et réduction significative du risque de réinfection

Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies.

SARS-CoV-2 infection in schools in a northern French city: a retrospective serological cohort study in an area of high transmission, France, January to April 2020

Characteristics Associated with Olfactory and Taste Disorders in COVID-19.

Syncytia formation by SARS-CoV-2-infected cells.

A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations

Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France.

Anti-HIV-1 antibodies trigger non-lytic complement deposition on infected cells.

3D Pasteur

Accelerated thymopoiesis and improved T-cell responses in HLA-A2/-DR2 transgenic BRGS-based human immune system mice.

A human immune system mouse model with robust lymph node development.

Correction: Stage-specific IFN-induced and IFN gene expression reveal convergence of type I and type II IFN and highlight their role in both acute and chronic stage of pathogenic SIV infection.

HIV Fusion in Dendritic Cells Occurs Mainly at the Surface and Is Limited by Low CD4 Levels

Zika virus induces massive cytoplasmic vacuolization and paraptosis-like death in infected cells.

Broadly neutralizing antibodies suppress post-transcytosis HIV-1 infectivity

Ultrasensitive HIV-1 p24 Assay Detects Single Infected Cells and Differences in Reservoir Induction by Latency Reversal Agents.

CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses

Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies

CD4-mimetic sulfopeptide conjugates display sub-nanomolar anti-HIV-1 activity and protect macaques against a SHIV162P3 vaginal challenge

[Antibodies that kill HIV-1-infected cells]

Antibodies capable of eliminating HIV-infected cells

Elimination of HIV-1-infected cells by broadly neutralizing antibodies

Dendritic Cells from HIV Controllers Have Low Susceptibility to HIV-1 Infection In Vitro but High Capacity to Capture HIV-1 Particles.

SAMHD1 Limits HIV-1 Antigen Presentation by Monocyte-Derived Dendritic Cells

Virus and Immunity

Long-term control of simian immunodeficiency virus (SIV) in cynomolgus macaques not associated with efficient SIV-specific CD8+ T-cell responses

IFITM proteins incorporated into HIV-1 virions impair viral fusion and spread

Plasmacytoid dendritic cell dynamics tune interferon-alfa production in SIV-infected cynomolgus macaques

Porcine colon explants in the study of innate immune response to Entamoeba histolytica

Towards the establishment of a porcine model to study human amebiasis

Expression and immunogenicity of the mycobacterial Ag85B/ESAT-6 antigens produced in transgenic plants by elastin-like peptide fusion strategy

Epithelial induction of porcine suppressor of cytokine signaling 2 (SOCS2) gene expression in response to Entamoeba histolytica